Clinical trials: sponsored by ModernaTX, Inc.
Relapsed or Refractory Multiple Myeloma
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study is designed to evaluate the safety and tolerability of mRNA-2736 in participants with RRMM.
- Trial name
- NCT05918250
- Testing
- mRNA-2736
- Where
- 13 sites in United States, Canada
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
The primary goal for this study is to evaluate the safety and reactogenicity of 3 dose levels of mRNA-1283 and 1 dose level of mRNA-1273 vaccine given to healthy adults in 2 doses, 28 days apart, and 1 dose level of mRNA-1283…
- Trial name
- NCT04813796
- Testing
- mRNA-1283, mRNA-1273
- Where
- 5 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2
Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States
The goal of this study is to add to the ongoing active and passive safety signal detection through signal refinement and, if needed, evaluation of potential safety signals related to taking the SARS-CoV-2 mRNA-1273 vaccine.
- Trial name
- NCT04958954
- Where
- United States
- Volunteers
- 50,000,000 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Coronavirus Disease (COVID-19)
Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination
This study is a long-term follow-up survey of Japanese people after their second vaccination with the Moderna COVID-19 vaccine. The study sponsor will not be involved in how the participants are treated but will provide…
- Trial name
- NCT04941144
- Testing
- COVID-19 Vaccine
- Where
- Japan
- Volunteers
- 8,538 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Healthy Participants
Use of Wearable Digital Sensors After mRNA Vaccination in Adults
The purpose of this study is to explore the physiological and behavioral impact of the immune response to vaccines after receipt of investigational or approved messenger ribonucleic acid (mRNA) vaccines using wearable medical…
- Trial name
- NCT05440318
- Testing
- Wireless wearable digital devices
- Where
- 4 sites in United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Human Metapneumovirus and Human Parainfluenza Infection
Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
This clinical study will assess the safety and immunogenicity of 2 dose levels of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine, in healthy adults (18 to 49 years of age) and 2 dose…
- Trial name
- NCT04144348
- Testing
- mRNA-1653
- Where
- 19 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2
Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older
This clinical study will assess the safety, reactogenicity, and immunogenicity of 2 dose levels of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-COV-2) vaccine in adults 18 years of age or older.
- Trial name
- NCT04405076
- Testing
- Biological: mRNA-1273, mRNA-1273.351
- Where
- 8 sites in United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2
A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
This study will investigate antibody levels with respect to time since receiving a COVID-19 booster shot. The study will be decentralized, where participants can complete all study tasks at home.
- Trial name
- disCOVEries (NCT05367908)
- Where
- United States
- Volunteers
- 1,501 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults
There are 2 parts to this study: a single ascending dose (single dose of mRNA-6231) part and a multiple ascending dose (repeat doses of mRNA-6231) part.
- Trial name
- NCT04916431
- Testing
- mRNA-6231
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2
A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
The goal of this study is to compare real-world effectiveness of the mRNA-1273 vaccine versus the BNT162b2 vaccine on medically attended COVID-19 and COVID-19 hospitalizations among fully vaccinated immunocompromise participants.
- Trial name
- NCT05366322
- Where
- United States
- Volunteers
- 124,879 people
- Sponsor
- ModernaTX, Inc.
Influenza
Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects
This clinical study will assess the safety, tolerability and immunogenicity of VAL-506440 in healthy adult subjects.
- Trial name
- NCT03076385
- Testing
- VAL-506440
- Where
- Germany
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Methylmalonic Acidemia, Propionic Acidemia
"The MaP Study": Mapping the Patient Journey in MMA and PA
Longitudinal, exploratory, natural history study of patients with MMA due to mut deficiency and PA to characterize the changes in blood disease biomarkers over time and the frequency and severity of clinical events related to…
- Trial name
- NCT03484767
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 97 people
- Sponsor
- ModernaTX, Inc.
Prevention of Chikungunya Virus Infection
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults
This is a Phase 1, FIH, single-center, randomized, placebo controlled, dose escalation study to evaluate the safety, tolerability, PK, and PD of mRNA-1944 in healthy adult subjects.
- Trial name
- NCT03829384
- Testing
- mRNA-1944
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Cytomegalovirus Infection
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1647 and mRNA-1443 cytomegalovirus vaccines in healthy adults
- Trial name
- NCT03382405
- Testing
- mRNA-1647, mRNA-1443
- Where
- 4 sites in United States
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects
This clinical study will assess the safety, tolerability and immunogenicity of VAL-339851 in healthy subjects.
- Trial name
- NCT03345043
- Testing
- VAL-339851
- Where
- United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Methylmalonic Acidemia (MMA), Metabolism, Inborn Errors
Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia
This First-in-Human (FIH) Phase 1/2 study will evaluate mRNA-3704 in patients with methylmalonic acidemia/aciduria (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency between 1 to 18 years of age with elevated plasma…
- Trial name
- NCT03810690
- Testing
- mRNA-3704
- Sponsor
- ModernaTX, Inc.
Human Metapneumovirus and Human Parainfluenza Infection
Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults
This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine in healthy adults.
- Trial name
- NCT03392389
- Testing
- mRNA-1653
- Where
- 3 sites in United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.